Skip to main content
An official website of the United States government

Everolimus

Placeholder slot
 (eh-veh-ROH-lih-mus)

Everolimus works by blocking the activity of a protein called mTOR, a kinase (enzyme) that is found in high amounts in some cancer cells. Blocking mTOR stops the growth of cancer cells and the growth of blood vessels that support tumor growth. Everolimus also lowers the body’s immune response. Everolimus is a targeted therapy drug that acts as a kinase inhibitor, an angiogenesis inhibitor, and an immunosuppressant.

US Brand Name(s)
Afinitor
Votubia
Zortress
FDA Approved
Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Everolimus is approved to treat:

The use of everolimus to treat cancer is approved for the Afinitor and Afinitor Disperz brands. Everolimus is also approved to treat transplant rejection. This use is approved for the Zortress brand.

Everolimus is also being studied in the treatment of other types of cancer.

More About Everolimus

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Everolimus - A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Targeted Therapy to Treat Cancer

Clinical Trials Accepting Patients

Find Clinical Trials for Everolimus - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated:
Email